Trials / Completed
CompletedNCT04441931
A Study of LY3832479 (LY-CoV016) in Healthy Participants
A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Immunogenicity of LY3832479 Given as a Single Intravenous Dose in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to learn more about the safety of LY3832479 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3832479 is in the bloodstream and how long it takes the body to eliminate it. Participation could last up to 16 weeks and may include up to 10 visits to the study center.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3832479 | Administered IV. |
| DRUG | Placebo | Administered IV. |
Timeline
- Start date
- 2020-06-19
- Primary completion
- 2020-10-02
- Completion
- 2020-10-02
- First posted
- 2020-06-22
- Last updated
- 2021-12-06
- Results posted
- 2021-12-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04441931. Inclusion in this directory is not an endorsement.